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Abstract
Background: The purpose of the study was to determine if the effect of llama OIF on LH secretion is mediated by
stimulation of the hypothalamus or pituitary gland.
Methods: Using a 2-by-2 factorial design to examine the effects of OIF vs GnRH with or without a GnRH
antagonist, llamas with a growing ovarian follicle greater than or equal to 8 mm were assigned randomly to four
groups (n = 7 per group) and a) pre-treated with 1.5 mg of GnRH antagonist (cetrorelix acetate) followed by 1 mg
of purified llama OIF, b) pre-treated with 1.5 mg of cetrorelix followed by 50 micrograms of GnRH, c) pre-treated
with a placebo (2 ml of saline) followed by 1 mg of purified llama OIF or d) pre-treated with a placebo (2 ml of
saline) followed by 50 micrograms of GnRH. Pre-treatment with cetrorelix or saline was given as a single slow
intravenous dose 2 hours before intramuscular administration of either GnRH or OIF. Blood samples for LH
measurement were taken every 15 minutes from 1.5 hours before to 8 hours after treatment. The ovaries were
examined by ultrasonography to detect ovulation and CL formation. Blood samples for progesterone measurement
were taken every-other-day from Day 0 (day of treatment) to Day 16.
Results: Ovulation rate was not different (P = 0.89) between placebo+GnRH (86%) and placebo+OIF groups
(100%); however, no ovulations were detected in llamas pre-treated with cetrorelix. Plasma LH concentrations
surged (P < 0.01) after treatment in both placebo+OIF and placebo+GnRH groups, but not in the cetrorelix groups.
Maximum plasma LH concentrations and CL diameter profiles did not differ between the placebo-treated groups,
but plasma progesterone concentrations were higher (P < 0.05), on days 6, 8 and 12 after treatment, in the OIF- vs
GnRH-treated group.
Conclusion: Cetrorelix (GnRH antagonist) inhibited the preovulatory LH surge induced by OIF in llamas suggesting
that LH secretion is modulated by a direct or indirect effect of OIF on GnRH neurons in the hypothalamus.
Background
In mammals, ovulation implies pulsatile secretion of
gonadotropin-releasing hormone (GnRH) from the
medio-basal nuclei of the hypothalamus into the hypo-
physeal portal system, followed by the release of LH
from the anterior pituitary into systemic circulation [1].
The classification of mammalian species as either spon-
taneous or induced ovulators is based on the type of
stimulus responsible for eliciting GnRH release from the
hypothalamus [2]. In spontaneous ovulators (e.g., cattle,
sheep, goats, pigs, horses), release of GnRH from the
hypothalamus is triggered when, in the absence of pro-
gesterone, systemic estradiol concentrations exceed a
certain threshold [3-5]. In induced ovulators (e.g., rab-
b i t s ,c a t s ,f e r r e t s ,c a m e l i d s ) ,h o w e v e r ,n e u r a ls i g n a l s
from mating-related stimulation trigger hypothalamic
GnRH, followed by the preovulatory release of LH from
the pituitary [2]. In spontaneous as well as in induced
ovulators, a surge in the circulating concentration of LH
is requisite for ovulation.
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(Lama pacos) and llamas (Lama glama) are induced ovu-
lators based on the observation that ovulation occurred
in > 95% of the females subsequent to mounting and
penile intromission compared to 14% of the females in
which intromission was not allowed. Later studies in lla-
mas [6,10,11] revealed that ovulation is preceded by a
sudden rise in plasma LH concentration beginning
within 15 minutes of mating.
Recent studies in llamas and alpacas [12-17] have
demonstrated the presence of a potent ovulation-indu-
cing factor (OIF) in the seminal plasma of these species,
challenging the notion that physical stimulation from
copulation is the only mating-related stimulus required
to trigger ovulation. In llamas, intramuscular administra-
tion of homologous seminal plasma [12-14] and purified
llama OIF [15-17] resulted in a rapid increase in plasma
LH concentration followed by ovulation [12,13,16,17],
similar to that observed after mating [6,10,11]. Biochem-
ical characterization and purification of llama OIF
revealed that this factor is a protein with a molecular
mass of ≥30 kDa, and is resistant to heat and enzymatic
d i g e s t i o n[ 1 5 ] .I nam o r er e c e n ts t u d y[ 1 6 ]l l a m aO I F
was identified as a 14 kDa protein, suggesting that this
molecule may be part of a larger protein complex or be
a bioactive form of a larger pro-hormone.
In llamas, the surge in plasma LH concentration trig-
gered by the administration of homologous seminal
plasma [12] or purified OIF [16,17] was more sustained
than that observed in GnRH-treated females [12]. In
this regard, alpaca seminal plasma induced LH secretion
in primary cultures of rat pituitary cells [18]. The same
effect has been observed in rat pituitary cultures treated
with whole seminal plasma [19] or bioactive fractions
isolated from the seminal plasma of Bactrian camels
[20,21], a related species where semen-induced ovulation
has also been described [22]. Moreover, the addition of
anti-GnRH antibodies to the rat pituitary cell cultures
did not suppress the effect of alpaca seminal plasma on
LH secretion [18], supporting the hypothesis that OIF
and GnRH are different molecules affecting LH pituitary
secretion in a different manner.
Although pervious studies have documented a direct
effect of OIF on pituitary gonadotropes in vitro, the role
of the hypothalamus in OIF-induced ovulation has not
been examined. Gonadotropin-releasing hormone
(GnRH) antagonists suppress pituitary gonadotropin
secretion by competitive blockade of GnRH receptors
[23-25]. Such molecules have been used to study the
role of gonadotropins (FSH and LH) in the control of
follicular development, ovulation and establishment and
maintenance of the CL in several animal species [26-32].
The use of a specific GnRH antagonist that can block
the pituitary response to exogenous and endogenous
GnRH provides an opportunity to determine, in vivo,
whether the OIF-induced preovulatory LH surge is a
result of activation of hypothalamic GnRH neurons or a
direct effect on the pituitary gland as previously sug-
gested by in vitro studies [18-21].
We used an in vivo llama model treated with the spe-
cific GnRH antagonist, cetrorelix acetate, to determine if
the effect of llama OIF on LH secretion is mediated by
the stimulation of the hypothalamus or the pituitary
gland.
Methods
Semen collection and seminal plasma preparation
Semen from 4 adult male llamas was collected twice per
week for two months prior to the start of the experi-
ment. Llamas were kept on pasture and were supple-
mented with hay. They were given water ad libitum and
were housed indoor at night. Semen was collected with
the use of an artificial vagina designed for sheep that
was fitted into a phantom mount built of wood and cov-
ered with a llama hide [33]. A total of 12 ejaculates were
collected from each male llama.
Llama semen was diluted 1:1 (v/v) with phosphate
buffered saline (PBS, Gibco, Grand Island, NY, USA)
and centrifuged for 30 minutes at 1500 × g at room
temperature. The supernatant was decanted to remove
spermatozoa and a drop was evaluated by microscopy to
confirm the absence of cells. If spermatozoa were
observed, the sample was centrifuged again in a like
manner. Sperm-free seminal plasma was stored at -80°C.
Upon thawing, the diluted seminal plasma was pooled
and sonicated to reduce viscosity, as previously
described [16]. After sonication, seminal plasma was
centrifuged at 10,000 × g for 20 minutes to remove par-
ticulate matter.
Llama OIF purification
Purification of OIF was performed in a 2-step proce-
dure, as previously described [16]. In brief, llama semi-
nal plasma was loaded into a Type 1 macro-prep
ceramic hydroxylapatite column (1 cm × 10 cm, 20 μm,
BIO-RAD laboratories, Hercules, CA, USA) previously
equilibrated with 10 mM sodium phosphate at a pH of
6.8. Elution was carried out at room temperature using
a lineal gradient with 350 mM sodium phosphate, pH
6.8, and a flow rate of 0.5 ml/min. An eluted fraction
showing a major protein on SDS-PAGE, was concen-
trated in phosphate buffered saline (PBS, pH 7.4) using
a 5 kDA cut- off membrane filter device (Vivaspin, Sar-
torius, Goettingen, Germany) and subsequently loaded
onto a gel filtration column (SEC, Hi Prep™ 26/60
Sepahacryl™ S-100, Amersham Laboratories, Piscat-
away, NJ, USA). The purification procedure was carried
o u ta tr o o mt e m p e r a t u r ea taf l o wr a t eo f0 . 5m lp e r
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Amersham Laboratories). Elution was performed isocra-
tically using PBS at pH 7.4. The bioactive fraction after
gel filtration was identified using an in vivo llama ovula-
tion bioassay [16] and it was defined as purified llama
OIF.
Experimental design
Non-pregnant, non-lactating female llamas, 4 to 8 years
of age, and weighing 135 to 150 kg were examined daily
by transrectal ultrasonography using a 7.5 MHz linear-
array transducer (Aloka, SSD-500, International Clinics,
Chile). Using a 2-by-2 factorial design to examine the
effects of OIF vs GnRH with or without a GnRH
antagonist, llamas with a growing ovarian follicle ≥8
mm were assigned randomly to four groups (n = 7 per
group) and a) pre-treated with 1.5 mg of GnRH antago-
nist (cetrorelix acetate, Cetrotide, Serono, Chile) fol-
lowed by 1 mg of purified llama OIF, b) pre-treated
with 1.5 mg of cetrorelix followed by 50 μgo fG n R H
(gonadorelin acetate, Ovalyse, Pfizer, Santiago, Chile), c)
pre-treated with a placebo (2 ml of saline) followed by 1
mg of purified llama OIF or d) pre-treated with a pla-
cebo (2 ml of saline) followed by 50 μgo fG n R H .P r e -
treatment with cetrorelix or saline was given as a single
slow intravenous dose 2 hours before intramuscular
administration of either GnRH or OIF. The dose of
cetrorelix (10 μg/Kg of body weight) was based on pre-
vious reports of effective suppression of pituitary LH
secretion in several animal species [27,31,32]. Treatment
with GnRH or OIF was given 2 hours after cetrorelix or
placebo administration, based on a previous report that
demonstrated rapid blockade of LH secretion after intra-
venous administration of the GnRH antagonist [34].
The ovaries were examined by transrectal ultrasono-
graphy every 12 hours from the day of treatment (day 0)
to day 2 to detect ovulation. Ultrasonographic examina-
tion was performed every-other-day thereafter until day
16 to monitor CL growth and regression. Ovulation was
defined as the sudden disappearance of a follicle ≥8m m
detected during the previous examination.
Blood samples for measurement of plasma LH con-
centration were collected in heparinized tubes every 15
minutes from 1.5 hours before to 8 hours after GnRH-
or OIF-treatment. A jugular catheter (o.d. 1.5 mm; i.d.
1.0 mm) was fixed in place one day before sampling to
minimize the effects of handling stress on plasma LH
concentration. After collection, blood samples were cen-
trifuged at 1500 × g for 10 min and the plasma was
stored at -20°C. Plasma LH concentration was deter-
mined by a double-antibody radioimmunoassay using
ovine radio-iodinated LH (LER 1374-A), ovine anti-
s e r u mC S U - 2 0 4a n do v i n eL Hs t a n d a r do L H - S 2 5
(provided by NIADDK, USA) in 200 μL duplicates, as
previously described [35]. Intra and inter-assay CV were
5 and 7%, respectively. The minimal detectable LH dose,
defined as 90% of buffer control, was 0.1 ng/mL. The
LH assay used in this study was validated previously for
LH determination in Pudú (Pudu puda) and alpacas
(Lama pacos) [36,37]. For this study, serial dilution of
llama plasma with high LH concentration was assayed
in the ovine RIA and was plotted against the standard
curve. Percentage of binding for each dilution was paral-
leled to the standard curve.
Blood samples were collected into heparinized tubes
(Vacutainer Systems, Becton Dickinson, Franklin Lakes,
NJ, USA) by jugular venipuncture every-other-day from
day 0 to day 16 to determine plasma progesterone concen-
tration. Blood samples were centrifuged at 1500 × g for 10
minutes and plasma was stored at -20°C. Plasma proges-
terone concentration was determined using a commercial
solid-phase radio-immunoassay kit (Coat-a-Count total
progesterone, DPC; Diagnostic Products Corporation, Los
Angeles, CA, USA) as previously reported [12]. The intra-
assay coefficients of variation were 4.5%, 2.3% and 2.6% for
the low, medium and high-reference plasma (means: 1.8,
3.5, and 16.5 ng/mL). The inter-assay coefficients of varia-
tion for low, medium and high-reference plasma were
7.0%, 5.0% and 6.0%, respectively.
The study was conducted during August to September
at the Universidad Austral de Chile, Valdivia, Chile (39°
38’S - 73° 5’W and 19 m above sea level). All procedures
were performed in accordance with the animal care pro-
tocols established by the Universidad Austral de Chile
and were revised and approved by its bioethics
committee.
Statistical analyses
Statistical analyses were performed using the Statistical
Analysis System software package SAS Learning Edition,
version 4.1 (SAS Institute Inc., Cary, NC, USA, 2006).
Serial data (plasma LH and progesterone concentration
profiles, and CL diameter) were analyzed as a 2-by-2
factorial design for repeated measures using the MIXED
procedure. The analysis included main effects of antago-
nist (cetrolix vs placebo), treatment (GnRH vs OIF),
time, and their interactions. If significant (P ≤ 0.05)
main effects or interactions were detected, Tukey’s post-
hoc test for multiple comparisons was used to locate
differences. Non-serial data (i.e. follicle diameter at the
time of treatment, first day CL detected, CL diameter
on day 8, maximum CL diameter, day of maximum CL
diameter and day of onset of luteal regression) were
compared using analyses of variance. Ovulation rates
were compared among groups by chi-square analysis.
All values are expressed as mean ± SEM.
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The diameter of the largest follicle at the time of treat-
ment did not differ among groups (P = 0.85, Table 1).
No ovulations were detected in llamas pre-treated with
cetrorelix, irrespective of subsequent treatment with
GnRH or llama OIF. The ovulation rate did not differ (P
= 0.89) between placebo+GnRH (6/7, 86%) and placebo
+OIF groups (7/7, 100%; Table 1).
During the 8-hour period after GnRH or OIF treat-
ment, plasma LH concentration increased and decreased
(P < 0.01) in both placebo-treated groups, but no
change in plasma LH concentration was detected in
cetrorelix-treated llamas (Figure 1). The first significant
increase in plasma LH concentration was detected 30
and 90 minutes after treatment in placebo+GnRH and
placebo+OIF groups, respectively (Figure 1). Maximum
plasma LH concentration did not differ (P = 0.16) between
the two placebo-treated groups and occurred 2.5 and 3
hours after treatment with OIF (5.1 ± 1.4 ng/mL) or
GnRH (5.8 ± 0.5 ng/mL), respectively (Figure 1). In the
placebo groups, plasma LH concentrations began to
decrease (P < 0.01) at 3 hours and 15 minutes after treat-
ment with GnRH and at 4 hours and 45 minutes after
treatment with OIF (Figure 1). Plasma LH concentration
decreased to basal levels by 5 hours after treatment
with GnRH, but had not yet declined to pretreatment
levels (P < 0.01) by the end of the 8-hour post-treatment
sampling period in those treated with OIF (Figure 1).
The diameter profile of the CL did not differ (P = 0.4)
between the two placebo-treated groups (Figure 2). No
differences were detected between the GnRH- and OIF-
treated groups regarding the first day of CL detection,
CL diameter, or the day of onset of CL regression
(Table 1). Plasma progesterone concentrations were
higher (P < 0.001) in both placebo-treated groups com-
pared with cetrorelix-treated groups where progesterone
concentration remained basal throughout the sampling
period (Figure 3). In both placebo-treated groups,
plasma progesterone concentration increased sharply to
peak values by day 8 after OIF (6.0 ± 0.7 ng/mL) and
GnRH (4.6 ± 0.5 ng/mL) treatment, and decreased shar-
ply afterwards to nadir by day 12 and 14, respectively
(Figure 3). Plasma progesterone concentration was
higher (P < 0.05) in the OIF- than the GnRH- treated
group on day 6, 8 and 12 after treatment.
Discussion
The results of the present study provide compelling evi-
dence that llama OIF stimulates LH pituitary release by
a previous action on the GnRH hypothalamic neurons.
The lack of stimulatory effect of OIF on LH secretion
after blocking GnRH receptors on gonadotropes sup-
ports the concept that the hypothalamus is the primary
target for the action of OIF in vivo. Therefore, it is valid
to suggest that pituitary LH secretion induced by OIF is
triggered by stimulation of hypothalamic GnRH release
within the hypophyseal portal vasculature. The adminis-
tration of cetrorelix acetate (1.5 mg; 10 μg/Kg) as a sin-
gle intravenous bolus 2 hours before treatment
effectively blocked pituitary GnRH receptors and sup-
pressed LH secretion, thereby preventing ovulation nor-
mally induced by the administration of a standard dose
of GnRH used in this species [38]. Intravenous adminis-
tration of cetrorelix in the present study blocked GnRH
receptors in gonadotropes within 2 hours, similar to the
effect described previously [34]. The immediacy of effect
allowed us to challenge the females with ovulation-indu-
cing treatments (GnRH or OIF) shortly after antagonist
administration, thus avoiding possible confounding
effects of longer exposure (e.g., loss of ovulatory capabil-
ity of dominant follicles).
Based on in vitro studies in which alpaca seminal
plasma [18], Bactrian camel seminal plasma [19], and its
bioactive fractions [20,21] are able to induce LH secre-
tion from rat pituitary cultures, we expected that purified
OIF would trigger an LH surge in llamas pre-treated with
Table 1 Effect (mean ± SEM) of pre-treatment with cetrorelix on ovulation and CL development in llamas treated with
GnRH or purified llama OIF (day 0 = day of treatment)
cetrorelix placebo
GnRH Llama OIF GnRH Llama OIF
(n = 7) (n = 7) (n = 7) (n = 7)
Follicle diameter at treatment (mm) 11.4 ± 0.4 11.2 ± 0.7 10.7 ± 0.4 10.9 ± 0.5
Ovulation rate (%) 0/7
a (0%) 0/7
a (0%) 6/7
b (86%) 7/7
b (100%)
1
st day CL detected * ————— ————— 2.3 ± 0.3 2.4 ± 0.4
CL diameter at day 8 (mm) * ————— ————— 13.7 ± 0.5 13.2 ± 0.4
Maximum CL diameter * ————— ————— 13.7 ± 0.5 13.2 ± 0.4
Day of maximum CL diameter * ————— ————— 8.3 ± 0.6 8.4 ± 0.4
Day of onset of CL regression * ————— ————— 10.3 ± 0.6 10.4 ± 0.4
a, b Proportions with different superscripts are different (P < 0.001).
* CL data was collected in 6 and 7 ovulated females in the placebo+GnRH and placebo+OIF treated group respectively.
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surge as effectively in the OIF-treated group as it did in
the GnRH-treated group, demonstrating that both mole-
cules require functional GnRH receptors at the gonado-
t r o p et oi n d u c ear i s ei np l a s m aL Hc o n c e n t r a t i o n .T h e
inference from these results is that purified OIF induces
pituitary LH secretion in vivo by stimulation of GnRH
release from the hypothalamus. The route by which OIF
reaches the hypothalamus, however, is not clear: OIF it is
a 14 kDa protein molecule [16] that presumably would
not easily cross the blood-brain barrier. However, authors
of recent report [39] suggest that peptides of peripheral
origin can reach neuronal axons at the median eminence
and elicit a direct or indirect effect on the hypothalamus.
The in vitro effect of alpaca or Bactrian camel seminal
plasma on LH secretion from pituitary cells and the pre-
sence of GnRH immuno-reactivity in human seminal
plasma [40,41] supported the hypothesis that OIF could be
related to the GnRH peptide. However, this has been ruled
out by observations that OIF induces a different in vivo LH
secretion pattern compared to GnRH [12], and the addition
of anti-GnRH antibodies to in vitro rat pituitary cell culture
did not block the LH-releasing effect of alpaca seminal
plasma [18]. Moreover, recent biochemical characterization
[15,16] has revealed that the molecular mass of llama OIF
is much greater than that of the decapeptide GnRH.
Although the hypothalamus is a primary target for the
action of llama OIF, the action at the level of the pitui-
tary gland remains unclear. Inconsistencies between our
results and in vitro effects of OIF [18-21] require further
investigation. A plausible explanation may be related to
the OIF concentration used in the in vitro studies. Puri-
fied OIF represents approximately 60% of the total pro-
tein in a llama ejaculate (i.e., OIF concentration of 3
mg/ml of ejaculate) [16]; therefore, primary pituitary
cultures stimulated with whole seminal plasma [18,19]
were exposed to very a high concentrations of OIF in
the media. Furthermore, seminal plasma is a complex
fluid where cytokines, among other components [42,43],
may influence gonadotrope LH secretion [44,45].
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Figure 1 Effect of cetrorelix pre-treatment on plasma LH concentration in llamas treated with GnRH or llama OIF.
x Within group, the
first significant increase from pretreatment concentration (P < 0.01).
y Within group, the maximum concentration (P < 0.01).
z Within group, the
first significant decrease from maximum concentration (P < 0.01). * Interval during which values in placebo+GnRH treated group were higher (P
< 0.01) than in both antagonist treated groups. ** Interval during which values in placebo+OIF treated group were higher (P < 0.01) than in
both antagonist treated groups. *** Within group, the last value is higher than the pre-treatment value (P < 0.01).
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Figure 2 Corpus luteum diameter in llamas given a placebo pre-treatment and treated with GnRH or llama OIF.
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Figure 3 Effect of pre-treatment with cetrorelix on plasma progesterone concentration in llamas treated with GnRH or llama OIF.
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reported for kisspeptin, a key signaling molecule in the
neuroendocrine regulation of gonadotropin secretion
[46-48]. Kisspeptin effectively induces LH secretion
from rat pituitary cell primary cultures [49,50], but
when sheep were passively immunized with anti-GnRH
antibodies, Kisspeptin did not elicit LH secretion from
the pituitary gland [51]. Differential effects observed
between in vitro and in vivo studies of kisspeptin have
been attributed to different dosages used [51].
In the present study, intramuscular administration of
purified OIF induced a surge release of LH resulting in
a high rate of ovulation in placebo pre-treated llamas. A
similar effect was demonstrated in previous studies in
which llamas were given homologous seminal plasma
[12-14] or purified OIF [15-17]. In the present study,
plasma LH concentration began to increase within 30
minutes of OIF treatment, peaked at 2.5 hours and
declined thereafter, similar to the pattern described in
response to mating [6,10,11], or intramuscular adminis-
tration of whole seminal plasma [12] or purified OIF
[16,17]. However, in the present study as well as in a
previous one (12), both the rise and fall in plasma LH
concentration were delayed in llamas treated with OIF
compared to those treated with GnRH, supporting the
notion that OIF and GnRH are different molecules. In
particular, LH release was sustained beyond the 8-hour
sampling period in OIF-treated animals whereas LH
concentration was basal by 6 hours after GnRH
treatment.
Previous studies support the concept that the ovula-
tion-inducing effect of llama and alpaca seminal plasma
is meditated via a systemic rather than a local route,
based on the differential ovulation rates obtained after
administration of seminalp l a s m ab yi n t r a m u s c u l a r
[12,13] and intrauterine routes [13]. While the design of
the earlier studies [13] did not rule out potential local
effects, results of the present study provide unequivocal
confirmation of a systemic route of action since block-
ade of GnRH receptors at the gonadotrope completely
abolished the LH surge and ovulation. This concept is
further reinforced by the observation that llama seminal
plasma induces a plasma LH surge in ovariectomized
llamas [52].
The luteotrophic effect of OIF treatment reported in
previous studies (12, 17) was confirmed in the present
study. Although the CL diameter profile did not differ
between OIF- and GnRH-treated llamas, plasma proges-
terone was elevated in the former. The relationship
between the degree of luteogenesis and the duration of
the preovulatory LH surge elicited by OIF warrants
further investigation, but is consistent with studies in
primates and laboratory species [53-56].
Based on the observation that the GnRH antagonist,
cetrorelix, blocked the preovulatory LH surge induced
by OIF in llamas, we conclude that the effect of OIF is
mediated at the level of the hypothalamic GnRH
neurons.
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